ロード中...
Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials
A primary goal of a phase II dose-ranging trial is to identify a correct dose before moving forward to a phase III confirmatory trial. A correct dose is one that is actually better than control. A popular model in phase II is an independent model that puts no structure on the dose-response relations...
保存先:
| 出版年: | Stat Med |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6606375/ https://ncbi.nlm.nih.gov/pubmed/31070807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.8167 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|